Add time:09/01/2019         Source:sciencedirect.com

Background(−)-Deprenyl and rasagiline are classified as selective inhibitors of B-type MAO. The DATATOP study revealed that the administration of (−)-deprenyl to untreated patients with Parkinson's disease (PD) significantly delays the need for levodopa therapy (Parkinson Study Group, 1989). Rasagiline was ineffective in this respect (Parkinson Study Group, 2002). The aim of this paper is to explain the reasoning behind the differentiation between (−)-deprenyl and rasagiline.

We also recommend Trading Suppliers and Manufacturers of Rasagiline (cas 136236-51-6). Pls Click Website Link as below: cas 136236-51-6 suppliers